Sickle cell disease treatment specialist Emmaus Life Sciences Inc (OTCMarkets: EMMA) announced on Tuesday the appointment of Willis C Lee as its new chief executive officer.
Lee was previously co-president and chief operating officer. He will continue to serve as chairman of the board.
Lee said: "We are working hard to improve the efficiency of the company by reorganising every level of our operations. We believe that these moves will better position us to serve our patients, clients, and shareholders, and equip us to face the challenges posed by the launch of generic L-glutamine. As the new CEO, I will ensure that we continue to grow our market presence in the Middle East and invest in research that will expand our pipelines and increase the value of the company."
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member